Funding round
Orca Bio Series D
Orca Bio, which works in cell therapy development in Menlo Park, raised $192M in a Series D round announced on 17 Jun 2020, led by Lightspeed Venture Partners and Undisclosed Investor. 9 firms took part. It is Orca Bio's first venture round on record.
$192M
Amount raised
Not disclosed
Post-money valuation
9
Investors
2 leads
Valuation
What this round says about the price
Orca Bio did not disclose a valuation in this round. It is Orca Bio's first venture round on record, 4 years after it was founded in 2016. It is 43% of the $442M Orca Bio has raised in the venture rounds on record. Orca Bio raised again 67 months later: a Series F round of $250M in Jan 2026.
Orca Bio's funding rounds
Orca Bio has 2 venture rounds on record and 1 other deal. This one is highlighted.
- Series D this round 17 Jun 2020, led by Lightspeed Venture Partners and Undisclosed Investor $192M
- Series F 1 Jan 2026, led by Lightspeed Venture Partners $250M
- Debt not a venture round 12 Jan 2026 amount not disclosed
Investors
Who put money in
Lightspeed Venture Partners and Undisclosed Investor led the round with 7 other firms.
Lead investors
- Lightspeed Venture Partners backs 454 venture-backed companies new investor
- Undisclosed Investor new investor
Use of proceeds
What the money is for
According to the announcement, the money goes to product development, scaling operations and working capital.
- Product development
- Scaling operations
- Working capital
Comparable rounds
How it compares
6 Series D rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $107M, and this round was 1.8 times the median. The closest in time, other companies' Series D rounds in Pharmaceutical Products:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Synthego Pharmaceutical Products | 26 Aug 2020 | $100M | $487M | 8VC and RA Capital |
| Pharmaceutical Products | 8 Dec 2020 | $181M | not disclosed | RTW Investments, LP and GT Fund |
| Pharmaceutical Products | 14 Nov 2019 | $35M | not disclosed | not named |
| Pharmaceutical Products | 10 Mar 2021 | $114M | not disclosed | LYZZ Capital and HBM Healthcare Investments |
| Pharmaceutical Products | 25 May 2021 | $65M | not disclosed | Cargill and Manna Tree Partners |
| Pharmaceutical Products | 15 Jun 2021 | $270M | not disclosed | not named |
Sources
Where this comes from
Reported by 6 sources.
Questions
Frequently asked
How much did Orca Bio raise in its Series D round?
Orca Bio raised $192M in its Series D round, announced in Jun 2020.
Who led Orca Bio's Series D round?
Lightspeed Venture Partners and Undisclosed Investor led it, with 8VC, DCVC, ND Capital, Mubadala and Kaiser Permanente Ventures and 2 more.
What was Orca Bio's valuation at the Series D round?
It was not disclosed.
How does it compare with other Series D rounds in Pharmaceutical Products?
6 Series D rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $107M, and this round was 1.8 times the median.
Did Orca Bio raise again after this round?
Yes: a Series F round in Jan 2026 of $250M.